Gene-Circuit Cell Therapy Market Report 2026

Gene-Circuit Cell Therapy Market Overview

• Gene-Circuit Cell Therapy market size has reached to $1.38 billion in 2025 • Expected to grow to $3.56 billion in 2030 at a compound annual growth rate (CAGR) of 20.8% • Growth Driver: Growing Adoption Of Personalized Medicine Fueling The Growth Of The Market Due To Advancements In Genomics And Tailored Treatment Approaches • Market Trend: Regeneron Pharmaceuticals Inc. Acquires 23andme Holding Co. To Accelerate Genomics-Driven Drug Discovery • North America was the largest region in 2025.

What Is Covered Under Gene-Circuit Cell Therapy Market?

Gene-circuit cell therapy is an advanced form of cell therapy where engineered cells are equipped with synthetic gene circuits that allow them to sense, process, and respond to specific biological signals in the body. It helps to provide controlled, targeted, and dynamic therapeutic responses such as releasing drugs, modulating immune activity, or correcting dysfunctional cellular behavior, enhancing precision and safety compared to conventional cell therapies. The main product types of gene-circuit cell therapy are autologous and allogeneic. Autologous therapy refers to a treatment approach in which a patient’s own cells are collected, genetically engineered with synthetic gene circuits to sense and respond to specific biological signals, and then reinfused back into the same patient. It utilizes advanced technologies such as clustered regularly interspaced short palindromic repeats (CRISPR), transcription activator-like effector nuclease (TALEN), zinc finger nuclease (ZFN), and others, and is used in applications for the treatment of oncology, genetic disorders, infectious diseases, and others. The key end users include hospitals and clinics, research institutes, biotechnology and pharmaceutical companies, and others.

What Is The Gene-Circuit Cell Therapy Market Growth Forecast?

The gene-circuit cell therapy market size is expected to see exponential growth in the next few years. It will grow to $3.56 billion in 2030 at a compound annual growth rate (CAGR) of 20.8%. The growth in the forecast period can be attributed to increasing commercialization of gene-circuit cell therapies, rising demand for controllable immunotherapies, expansion of oncology-focused pipelines, growing adoption of allogeneic platforms, advancements in scalable cell manufacturing. Major trends in the forecast period include increasing adoption of synthetic gene circuits in cell therapy, rising development of logic-controlled immune cells, growing use of off-the-shelf allogeneic therapies, expansion of dynamic cellular response systems, enhanced focus on treatment safety and control.

Global Gene-Circuit Cell Therapy Market Segmentation

1) By Product Type: Autologous, Allogeneic 2) By Technology: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), Transcription Activator-Like Effector Nuclease (TALEN), Zinc Finger Nuclease (ZFN), Other Technologies 3) By Application: Oncology, Genetic Disorders, Infectious Diseases, Other Applications 4) By End-User: Hospitals And Clinics, Research Institutes, Biotechnology And Pharmaceutical Companies, Other End Users Subsegments: 1) By Autologous: Chimeric Antigen Receptor (CAR)-T Cell Therapies, T-Cell Receptor (TCR)-T Cell Therapies, Natural Killer (NK) Cell Therapies, Stem Cell-Based Therapies 2) By Allogeneic: Off-The-Shelf Chimeric Antigen Receptor (CAR)-T Cell Therapies, Off-The-Shelf Natural Killer (NK) Cell Therapies, TT-Cell Receptor (TCR)-T Cell Therapies, Stem Cell-Derived Therapies

What Is The Driver Of The Gene-Circuit Cell Therapy Market?

The growing adoption of personalized medicine is expected to drive the growth of the gene-circuit cell therapy market going forward. Personalized medicine refers to a medical approach that tailors treatment and prevention strategies to an individual’s unique genetic makeup, lifestyle, and environment. The increasing adoption of personalized medicine is primarily due to advancements in genomics, which enable precise identification of genetic variations and tailored treatments for individuals. Gene-circuit cell therapy supports personalized medicine by enabling targeted and programmable treatment approaches, making it ideal for complex and chronic diseases. It enhances therapeutic precision by tailoring interventions to individual patient needs, improving treatment effectiveness and overall health outcomes. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a significant increase from the 12 approved in 2022. Therefore, the growing adoption of personalized medicine is driving the growth of the gene-circuit cell therapy industry.

Key Players In The Global Gene-Circuit Cell Therapy Market

Major companies operating in the gene-circuit cell therapy market are Tmunity Therapeutics Inc., Ginkgo Bioworks Holdings Inc., Arcellx Inc., Beam Therapeutics Inc., CRISPR Therapeutics AG, Intellia Therapeutics Inc., Orchard Therapeutics plc, Fate Therapeutics Inc., Rubius Therapeutics Inc., BlueRock Therapeutics LP (a subsidiary of Bayer AG), Precigen Inc., SparingVision, Alaunos Therapeutics Inc., Cartesian Therapeutics Inc., Lyell Immunopharma Inc., Synlogic Inc., Senti Biosciences Inc., Autolus Therapeutics plc, Cellectis S.A., Sotio Biotech

Global Gene-Circuit Cell Therapy Market Trends and Insights

Major companies operating in the gene-circuit cell therapy market are focusing on developing advanced therapeutic platforms, such as CRISPR-based gene editing systems, to enhance treatment precision, improve therapeutic outcomes, and address previously incurable genetic diseases. CRISPR-based gene editing systems refer to innovative technologies that enable precise modifications to the genome, allowing for the correction of genetic defects or the introduction of therapeutic genes into cells. For instance, in December 2023, Vertex Pharmaceuticals Inc., a US-based biopharmaceutical company, partnered with CRISPR Therapeutics Inc., a US-based biotechnology research company, and received conditional marketing authorization from the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) for CASGEVY (exagamglogene autotemcel, exa-cel). It is indicated for patients aged 12 and older with sickle cell disease (SCD) and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia (TDT). Casgevy works by editing a patient’s hematopoietic stem cells to reactivate fetal hemoglobin production, which reduces or eliminates disease symptoms and offers a potential functional cure for these conditions.

What Are Latest Mergers And Acquisitions In The Gene-Circuit Cell Therapy Market?

In May 2025, AstraZeneca PLC, a UK-based pharmaceutical company, acquired EsoBiotec for an undisclosed amount. With this acquisition, AstraZeneca aims to accelerate and scale its in vivo cell therapy capabilities, particularly to make transformative cancer and immune-mediated disease treatments more accessible and efficient. EsoBiotec BV is a Belgium-based biotechnology company that specializes in developing provides a gene-circuit cell therapy.

Regional Insights

North America was the largest region in the gene-circuit cell therapy market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Gene-Circuit Cell Therapy Market?

The gene-circuit cell therapy consists of revenues earned by entities by providing services such as cell engineering and programming, patient monitoring, therapeutic response customization, and clinical trial support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gene-circuit cell therapy also includes sales of engineered therapeutic cells, synthetic gene circuit constructs, cell therapy kits, reagents, and supporting delivery systems or devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Gene-Circuit Cell Therapy Market Report 2026?

The gene-circuit cell therapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the gene-circuit cell therapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.